Design, synthesis,
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
22 Apr 2022
22 Apr 2022
Historique:
received:
19
02
2022
accepted:
22
04
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Fourteen recent thiazolidine-2,4-diones bearing furan and/or thiophene heterocyclic rings have been designed, synthesized and assessed for their anticancer activities against four human tumor cell lines HepG2, A549, MCF-7 and HCT-116 targeting both VEGFR-2 and EGFR tyrosine kinases. Molecular design was carried out to investigate the binding mode of the proposed compounds with VEGFR-2 and EGFR receptors. HepG2 was the most susceptible cell line to the influence of our derivatives. Compounds 5g and 4g revealed the highest activities against HepG2 (IC
Identifiants
pubmed: 35496328
doi: 10.1039/d2ra01119k
pii: d2ra01119k
pmc: PMC9045483
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12913-12931Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
PLoS One. 2013 Jul 16;8(7):e68237
pubmed: 23874557
Bioorg Chem. 2020 Nov;104:104350
pubmed: 33142416
Bioorg Chem. 2020 Sep;102:104059
pubmed: 32653608
Oncotarget. 2017 Jun 13;8(24):38568-38580
pubmed: 28445134
J Thorac Oncol. 2021 Feb;16(2):205-215
pubmed: 33096270
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
Eur J Med Chem. 2016 Jan 1;107:165-79
pubmed: 26590508
Eur J Med Chem. 2014 Jan;71:1-14
pubmed: 24269511
J Mol Graph Model. 2009 Feb;27(6):751-8
pubmed: 19138543
Patholog Res Int. 2011;2011:572706
pubmed: 21747968
Bioorg Chem. 2020 Dec;105:104399
pubmed: 33113414
Bioorg Med Chem. 2015 Oct 1;23(19):6497-509
pubmed: 26344591
Bull Exp Biol Med. 2010 Nov;149(6):749-52
pubmed: 21165437
Arch Pharm (Weinheim). 2020 Sep;353(9):e2000079
pubmed: 32515896
Arch Pharm (Weinheim). 2020 Aug;353(8):e2000068
pubmed: 32510731
Arch Pharm (Weinheim). 2021 Nov;354(11):e2100201
pubmed: 34411344
J Med Chem. 2015 May 14;58(9):4066-72
pubmed: 25860834
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Sci Rep. 2015 Nov 16;5:16750
pubmed: 26568452
Arch Pharm (Weinheim). 2022 Feb;355(2):e2100237
pubmed: 34862655
SLAS Discov. 2018 Sep;23(8):807-814
pubmed: 29437525
Anal Biochem. 2006 Sep 15;356(2):273-81
pubmed: 16814737
Bioorg Chem. 2016 Aug;67:139-47
pubmed: 27388635
J Thorac Oncol. 2016 Apr;11(4):556-65
pubmed: 26724471
J Clin Invest. 2002 Oct;110(7):923-32
pubmed: 12370270
PLoS One. 2013 Jul 05;8(7):e68566
pubmed: 23861918
Blood Cells Mol Dis. 2007 May-Jun;38(3):258-68
pubmed: 17344076
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Eur J Med Chem. 2010 Nov;45(11):5420-7
pubmed: 20869793
Eur J Med Chem. 2017 Jan 5;125:245-254
pubmed: 27688180
Fertil Steril. 2010 Apr;93(6):2042-7
pubmed: 19342033
Bioorg Med Chem. 2010 Aug 1;18(15):5738-48
pubmed: 20621496
Cancer Treat Rev. 2012 Nov;38(7):825-33
pubmed: 22677191
Appl Environ Microbiol. 1999 Aug;65(8):3727-9
pubmed: 10427074
Expert Opin Investig Drugs. 2014 Apr;23(4):501-10
pubmed: 24597633
Pharmacol Ther. 2011 Jul;131(1):80-90
pubmed: 21439312
Bioorg Med Chem. 2017 Jun 15;25(12):2956-2970
pubmed: 28487127
Bioorg Chem. 2021 Oct;115:105186
pubmed: 34314914
Eur J Med Chem. 2017 Sep 29;138:669-688
pubmed: 28711702
ACS Chem Biol. 2014 Jun 20;9(6):1230-41
pubmed: 24730530
Bioorg Chem. 2019 Jul;88:102944
pubmed: 31051400
Bioorg Chem. 2021 Mar;108:104669
pubmed: 33515863
Eur J Med Chem. 2017 Oct 20;139:674-697
pubmed: 28850922
Biol Pharm Bull. 2011;34(12):1785-8
pubmed: 22130231
Trends Pharmacol Sci. 2015 Jul;36(7):422-39
pubmed: 25975227